HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
LPCN
Lipocine Inc.
There isn't enough reported data to score LPCN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
LPCN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
LPCN's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
LPCN PE Valuation
LPCN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
LPCN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect LPCN's losses to shrink, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
LPCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.27 |
| Q2 2026 | -$1.79 | -$0.93 |
| Q1 2026 | -$1.88 | -$0.87 |
| Q4 2025 | -$1.69 | -$1.69 |
| Q3 2025 | -$1.01 | +$0.48 |
| Q2 2025 | -$0.86 | +$1.45 |
| Q1 2025 | -$1.01 | +$1.42 |
| Q4 2024 | -$0.00 | +$3.77 |
LPCN is still losing money, but far less than before: $1.28 per share over the past year, against $8.50 at its worst in late 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over LPCN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over LPCN on profitability, with a higher operating margin.
LPCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3M | +1899% |
| Q2 2026 | $190.1K | -69% |
| Q1 2026 | $119.4K | +27% |
| Q4 2025 | $1.1M | -67% |
| Q2 2025 | $622.8K | +595% |
| Q1 2025 | $93.9K | -99% |
| Q4 2024 | $3.5M | +1515% |
| Q1 2024 | $7.6M | +13752% |
LPCN's revenue is recovering but still below its 2021 peak: $2M last quarter, up 1899% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | +2896 points |
| Q2 2026 | -1495% | -1109 points |
| Q1 2026 | -3224% | -997 points |
| Q4 2025 | -220% | -264 points |
| Q3 2025 | -2934% | N/A |
| Q2 2025 | -386% | +3290 points |
| Q1 2025 | -2227% | -2269 points |
| Q4 2024 | 44% | +1244 points |
LPCN's operating margin was −38% last quarter, up 2896 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
LPCN has the stronger cash trend. Its trailing FCF is up 26% versus its history, compared with HIMS at down 84%.
LPCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3M | -$1.1M |
| Q1 2026 | -$2.3M | -$287.9K |
| Q4 2024 | $1.7M | +$3.7M |
| Q4 2023 | -$2M | -$95.8K |
| Q3 2023 | -$2.6M | +$592.1K |
| Q2 2023 | -$3.3M | -$253K |
| Q1 2023 | -$3.9M | -$19.9K |
| Q3 2022 | -$3.2M | +$3.8M |
LPCN has burned cash in almost every quarter: −$9M over the past year, against −$5M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over LPCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
LPCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +27.6K shares |
| 1 year | +54% | +2.9M shares |
| 3 years | +57% | +3M shares |
| 5 years | +59% | +3.1M shares |
| Available history | +239% | +5.8M shares |
LPCN has 8M diluted shares, up 54% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
LPCN Net Leverage
LPCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
LPCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.9 | Neutral |
| Stochastic | 9.5 | Oversold |
LPCN's weekly RSI is 35 (neutral) and its Stochastic is 10 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
LPCN PE vs Healthcare Sector
| Metric | LPCN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LPCN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
LPCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.69 | 4.1% below |
| 20 week MA | $2.01 | 19% below |
| 50 week MA | $3.99 | 59% below |
| 100 week MA | $3.69 | 56% below |
| 200 week MA | $4.28 | 62% below |
LPCN is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over LPCN on returns for 2026, with the stronger performance.
LPCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.04 | $24.1 | +300% |
| 2021 | $24.1 | $18.0 | -25% |
| 2022 | $18.0 | $6.90 | -62% |
| 2023 | $6.90 | $2.79 | -60% |
| 2024 | $2.79 | $4.76 | +71% |
| 2025 | $4.76 | $5.23 | +9.9% |
| 2026 YTD | $5.23 | $1.62 | -69% |
LPCN's yearly returns have swung widely, from +300% in 2020 to −62% in 2022. It's down 69% so far in 2026.